Close Menu

Mutually Beneficial

Jeff Bluestone tells Xconomy San Francisco that, as a result of recent advances in genomics, partnerships between academia and industry are both "logical and appropriate." Industry's impressive investment in data generation "has actually left a hole" in terms of functional interpretation, says Bluestone, an executive vice chancellor and provost at the University of California, San Francisco.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The National Health Service is to offer Novartis's Zolgensma for spinal muscular atrophy later this year, according to the Guardian.

Nature News reports the US National Institutes of Health is investing in studies of the long-term effects of COVID-19.

Taiwan is to launch a pilot program offering genetic testing to cancer patients, the Taipei Times reports.

In PLOS this week: loci linked to protection against tuberculosis, identification of loci associated with increased risk of squamous cell carcinoma of the aerodigestive tract, and more.